Despite the film's delayed release and so much of the plot leaking online, Spider-Man: No Way Home continues to soldier on at the box office and exceed expectations as the flick recently became the first film to achieve a one-billion-dollar-gross since 2019. Even with major franchise releases also taking place following their own delay, including The King's Man and The Matrix Resurrections, Tom Holland's wall-crawler threequel remains atop the box office.
For now, the MCU has no big-screen releases planned until May, but a Marvel project will be back in theaters in April with Sony's Morbius finally coming to town.
Sony's latest Spider-Man spin-off will star Jared Leto as Dr. Michael Morbius who inadvertently turns himself into a vampire in trying to find a cure for his rare blood disease. To date, Morbius has suffered seven delays with the latest pushing it from January 28 to April 1, 2022.
While many assumed this came down to the Omicron variant of COVID-19 beginning to take the world by storm, a recent report has offered another explanation for the delay that surprisingly throws Spider-Man: No Way Home under the bus.
No Way Home Caused Morbius' Delay
According to a recent report from Deadline, the ongoing box office success of Spider-Man: No Way Home was one catalyst in Morbius' latest delay.
After grossing over $1.37 billion worldwide to date, Marvel's latest Multiverse blockbuster looks to continue selling tickets on theater screens through the New Year - tickets that would otherwise be sold for Jared Leto's vampire flick that would've been in theaters at the same time.
Given this, it appears Morbius' delay was done in part to allow No Way Home to continue succeeding and only further its box office final total while also giving Morbius the room it needs to breathe as Sony looks to establish their latest Spider-Man spin-off.
How Will Morbius Perform at the Box Office?
Having grossed more than a billion dollars at the box office already, Spider-Man: No Way Home was the biggest film of 2021 by a significant margin, and its success is now seeping into 2022. With the Multiversal threequel still sitting atop the box office, it's a logical move for Sony to avoid placing any competition in its path.
Both Venom and its sequel were great box office successes with Let There Be Carnage earning $500 million worldwide during the pandemic. While these impressive performances demonstrate a clear interest in Sony's Marvel universe, Morbius doesn't have anywhere near the established brand recognition of the iconic alien symbiote.
An important note is that Let There Be Carnage benefited strongly from talk of its shocking Spider-Man-centric post-credits scene. Unless Jared Leto's Marvel debut includes a jaw-dropping moment of that nature, it's rather unlikely that Morbius will generate as much discussion as Venom 2 even as fans continue to speculate which corner of the Multiverse it takes place in.
As the pandemic rages on, it's also impossible to predict what the COVID-19 situation will be when Morbius reaches its April release. With new Variants popping up on a regular basis, it's anyone's guess what the situation will be when Spring 2022 rolls around.
Box office enthusiasts will be able to garner a better picture of how Morbius will perform closer to when it hits theaters on April 1, 2022.